News|Podcasts|November 17, 2026

Pharmaceutical Executive Daily: FDA Approves Cosentyx and Wilserdly

Gilead signs royalty-free licensing deals to broaden Ebola antiviral access, FDA approves Cosentyx for polymyalgia rheumatica and Wilserdly for ESR1-mutated breast cancer, and Infinitus’s Ankit Jain talks agentic AI’s role in pharma’s commercial model.

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.

In today’s Pharmaceutical Executive Daily, Gilead Sciences signs royalty-free licensing deals with three generic manufacturers to broaden access to its investigational antiviral obeldesivir across 127 countries, FDA approves two new therapies, Novartis’s Cosentyx for polymyalgia rheumatica and Roche’s Wilserdly for ESR1-mutated advanced breast cancer, and Ankit Jain of Infinitus speaks on how agentic AI needs to deliver more than productivity gains for pharma’s commercial teams.

Gilead Sciences has signed royalty-free voluntary licensing agreements with Dr. Reddy’s Laboratories, Eva Pharma, and Ferozsons Laboratories to manufacture and supply obeldesivir, an investigational antiviral being studied as post-exposure prophylaxis for Ebola Bundibugyo virus disease, across 127 mostly low- and lower-middle-income countries, including every African nation that has reported cases in the current outbreak. The deals, modeled on Gilead’s earlier remdesivir Covid-19 licenses, are meant to build manufacturing and supply capacity ahead of results from the Ebo-pep trial, a partner-led Phase III field study; Jaime McCoy, vice president of Gilead Patient Solutions, says the agreements reflect the company’s commitment to “preparing for future access while clinical research is ongoing.”

Two FDA approvals this week broaden treatment options in rheumatology and oncology. FDA approves Novartis’s Cosentyx, making it the first and only anti-IL-17 biologic cleared for polymyalgia rheumatica, after the Phase III Replenish trial showed secukinumab doubled the likelihood of sustained remission in a disease where up to 40% of patients relapse on steroids within a year. Separately, FDA approves Roche’s Wilserdly in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer, after the Phase III EvERA trial showed a 62% reduction in the risk of progression or death versus standard therapy.

Finally, Pharmaceutical Executive speaks with Ankit Jain, chief executive officer and founder of Infinitus, on how agentic AI models are reshaping pharma’s commercial operations. Jain argues the technology needs to drive broader industry change rather than just productivity gains, pointing to agents that log CRM data and prep field reps during drive time, and always-available virtual reps that can answer physician questions around the clock instead of only during scheduled sales visits.

Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com.


Related to this article

Pharmaceutical Executive Daily
FDA reportedly shelves its Commissioner’s National Priority Voucher program, Eli Lilly breaks ground on a $3.5 billion Pennsylvania manufacturing site for next-generation obesity treatments, and Parexel’s Stacy Hurt on how small protocol decisions can become enrollment and retention barriers.
Pharmaceutical Executive Daily
FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter the clinical research process, and Ignite Proteomics’ Dr. Brian Corgiat on adjusting for tumor mutations in treatment decisions.